Select Page

KALY – Kali-Extracts Announces 25 mg CBD Extract Formulation For $600 Million Cannabis Beverage Market

KALY – Kali-Extracts Announces 25 mg CBD Extract Formulation For $600 Million Cannabis Beverage Market

KALY indicates its formulation will be on shelves infused into its first beverage within the next 30 days.


Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced finalizing it’s all new 25 mg CBD Extract formulation for beverage infusion.

KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC: PURA) (“PURA”) leading EVERx CBD Sports Water.  Few CBD beverages today even have 5 mg of CBD and now KALY will supply a 25 mg formulation.

Management thoroughly evaluated the 25 mg CBD formulation for infusion into a drink that is clear looking and tasting in a suspension with an effective retail shelf-life.  KALY indicates its formulation will be on shelves infused into its first beverage within the next 30 days. KALY earlier this week announced that the State of Texas plans to remove hemp as a controlled substance next week in conjunction with the United States 2018 Farm Act is just the type of market condition management is looking for to support the implantation of the previously announced cannabis extraction lab to be dedicated to the 100 acre hemp farm to be operated by partner Nouveau (USOTC: NOUV).

KALY and NOUV plan to partner on the development of a proprietary hemp cultivar dedicated to the advancement of KALY’s pharmaceutical extract developments.  The continuing liberalization of cannabis laws, such as the hemp removal as a controlled substance in Texas, supports the work KALY is advancing.Last week, KALY published a research report on the recent pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates using an extract derived from KALY’s patented cannabis extraction process.  The report details the study method and the significance of the study.  The report includes specific findings and due to the substantial findings, the report includes guidelines for next stage tests.The full report can be read on the company’s website at

Goldman Small Cap Research Report has published an analyst research report on KALY that highlights KALY’s cannabis pharmaceutical value.  The report is available under “research” on the OTCMarkets website. The research report is the first report from Goldman Small Cap Research as part of an ongoing research engagement. The report outlines the company’s current positioning and potential, upcoming milestones. The report is intended to augment the current information available on the OTCMarkets website. The report is also available to read or download, along with associated disclosures and disclaimers, at

KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies.  In addition developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.To learn more about the company visit

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

Frederick Ferri
[email protected]
(214) 210-0459

0 0 votes
Article Rating
Inline Feedbacks
View all comments

Join Our Newsletter

Get stock alerts, news & related alerts straight to your inbox!

Would love your thoughts, please comment.x